Lexeo Therapeutics, Inc. Common Stock (LXEO)
USD 2.14
(8.08%)
USD 2.14
(8.08%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -59.49 Million | -54.56 Million | -44.18 Million | -3.13 Million |
| Net Income | -66.39 Million | -59.27 Million | -50.62 Million | -5.15 Million |
| Depreciation & Amortization | 1.84 Million | 1.14 Million | 13 Thousand | - |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 3.04 Million | 1.78 Million | 386 Thousand | - |
| Change in working capital | 1.48 Million | 1.79 Million | 6.04 Million | 150.15 Thousand |
| Other non-cash items | 530 Thousand | 4.49 Million | -2.6 Million | 1.86 Million |
| Investing Cash Flow | -165 Thousand | -901 Thousand | -188 Thousand | - |
| Investments in PPE | -165 Thousand | -901 Thousand | -188 Thousand | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -50 Thousand | - | - | - |
| Financing Cash Flow | 103.79 Million | 189 Thousand | 150.85 Million | 32.37 Million |
| Debt repayment | -425 Thousand | -163 Thousand | - | -2.6 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 100.25 Million | 352 Thousand | 150.85 Million | 29.77 Million |
| Other Financing Activities | 3.96 Million | 352 Thousand | 150.85 Million | 32.37 Million |
| Accounts receivables | - | - | - | - |
| Accounts payables | -180 Thousand | -426 Thousand | 3.01 Million | 44.31 Thousand |
| Inventory | - | - | - | - |
| Other working capital | 1.66 Million | 2.21 Million | 3.02 Million | 105.83 Thousand |
| Cash at beginning of period | 80.58 Million | 135.86 Million | 29.37 Million | 127.86 Thousand |
| Cash at end of period | 124.71 Million | 80.58 Million | 135.86 Million | 29.37 Million |
| Capital Expenditure | -165 Thousand | -901 Thousand | -188 Thousand | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | 44.13 Million | -55.27 Million | 106.48 Million | 29.24 Million |
| Free Cash Flow | -59.66 Million | -55.46 Million | -44.37 Million | -3.13 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -21.23 Million | -21.68 Million | -66.39 Million | -14.18 Million | -20.1 Million | -13.44 Million |
| Depreciation & Amortization | 496 Thousand | 476 Thousand | 1.84 Million | 490 Thousand | 460 Thousand | 446 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.84 Million | 2.33 Million | 3.04 Million | 804 Thousand | 873 Thousand | 969 Thousand |
| Change in working capital | -2.25 Million | 4 Million | 1.48 Million | -1.34 Million | 4.55 Million | -1.16 Million |
| Other non-cash items | 2.77 Million | 2.64 Million | 530 Thousand | 258 Thousand | 272 Thousand | 3.76 Million |
| Investing Cash Flow | -218 Thousand | -193 Thousand | -165 Thousand | -73 Thousand | -53 Thousand | -39 Thousand |
| Investments in PPE | -218 Thousand | -193 Thousand | -165 Thousand | -73 Thousand | -53 Thousand | -39 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -5000.00 | -8000.00 | -50 Thousand | - | - | - |
| Financing Cash Flow | 291 Thousand | 88.65 Million | 103.79 Million | 100.07 Million | 3.91 Million | -94 Thousand |
| Debt repayment | -74 Thousand | -109 Thousand | -425 Thousand | -105 Thousand | -107 Thousand | -103 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -13 Thousand | - | - | - | - | - |
| Common Stock Issuance | 378 Thousand | 88.75 Million | 100.25 Million | 100.25 Million | 30 Thousand | 8862.00 |
| Other Financing Activities | 419 Thousand | 10 Thousand | 3.96 Million | 100.17 Million | 4.01 Million | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.05 Million | 639 Thousand | -180 Thousand | 394 Thousand | 290 Thousand | -1.9 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -3.31 Million | 3.36 Million | 1.66 Million | -1.74 Million | 4.26 Million | 742.86 Thousand |
| Cash at beginning of period | 195.06 Million | 124.71 Million | 80.58 Million | 38.7 Million | 45.53 Million | 62.11 Million |
| Cash at end of period | 174.98 Million | 198.31 Million | 124.71 Million | 124.71 Million | 38.7 Million | 45.53 Million |
| Capital Expenditure | -218 Thousand | -193 Thousand | -165 Thousand | -73 Thousand | -53 Thousand | -39 Thousand |
| Effect of forex changes on cash | - | - | - | - | 3.25 Million | - |
| Net cash flow / Change in cash | -20.07 Million | 73.59 Million | 44.13 Million | 86.01 Million | -6.83 Million | -16.57 Million |
| Free Cash Flow | -20.37 Million | -15.06 Million | -59.66 Million | -14.05 Million | -14 Million | -13.23 Million |
6049
ENTEL
115390
GHY
600726
600779